DDInter157 DDInter1676
Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides. In March 2020, a small
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Azithromycin {u} (Compound) resembles {v} (Compound) Telithromycin
Azithromycin {u} (Compound) resembles {v} (Compound) Dirithromycin
Azithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Azithromycin {u} (Compound) binds {v} (Gene) CYP3A4
Azithromycin {u} (Compound) upregulates {v} (Gene) CDH3
Azithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Macrolides
Azithromycin {u} (Compound) downregulates {v} (Gene) TSTA3
Azithromycin {u} (Compound) causes {v} (Side Effect) Face oedema
Azithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Azithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Azithromycin (Compound) resembles Telithromycin (Compound)
Azithromycin (Compound) resembles Dirithromycin (Compound)
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Azithromycin (Compound) binds CYP3A4 (Gene)
Azithromycin (Compound) upregulates CDH3 (Gene)
Azithromycin (Compound) is included by Macrolides (Pharmacologic Class)
Azithromycin (Compound) downregulates TSTA3 (Gene)
Azithromycin (Compound) causes Face oedema (Side Effect)
Azithromycin may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli